SIRPA and inflammatory bowel disease: It would be important to investigate whether the presence of < 9.4% of SIRPα/β+memory B cells also predicts ADA formation in patients with other autoimmune diseases treated with biologics [e.g., inflammatory bowel disease (IBD) treated with adalimumab] or in RA patients treated with other biologics (e.g., infliximab).